The Slow Responder: not absorbing, not taking, or not susceptible?
For healthcare organizations and professionals (B2B) · Physician-led · Updated 2026-07-12 · CLIA #45D2048957 · CAP #8722734
Same picture at month two, three different problemsCLIA #45D2048957 · CAP #8722734 · Same-day results · Walk-ins welcome
Three very different problems look the same at month two. The serum concentration after an observed dose is the one measurement that separates under-exposure (fix the dose) from acquired resistance (change the regimen) and from non-adherence (support the patient). Auspicious Laboratory measures ten anti-TB drugs by LC-MS/MS in serum, in-house in Houston (CLIA #45D2048957 · CAP #8722734). Under-exposure is common in HIV co-infection, diabetes, gastrectomy and chronic diarrhoea — and it is routinely mislabelled as treatment failure.
Three patients look identical at month two: still culture-positive, still symptomatic, DOT documented. One is not swallowing the pills. One is swallowing them and not absorbing them. One is absorbing them and the organism does not care. Same picture, three different diseases of the treatment.
How do you tell malabsorption apart from non-adherence and acquired resistance?
| Non-adherence | Malabsorption / under-exposure | Acquired resistance | |
|---|---|---|---|
| Serum drug level after an observed dose | Therapeutic (the observed dose was taken) | Low | Therapeutic |
| Culture conversion | Delayed | Delayed | Delayed |
| DST result | Susceptible | Susceptible | Resistant |
| Right response | Adherence support, DOT/VOT | Dose adjustment — not a new regimen | Regimen change |
The row that separates the middle column from the others is the serum concentration. Without it, an under-exposed patient is often labelled a treatment failure and pushed onto a second-line regimen with more toxicity and a longer course — for a problem a dose adjustment would have solved.
Who under-absorbs?
- HIV co-infection — enteropathy plus interactions with ART.
- Diabetes — gastroparesis and, independently, lower rifampin exposure and slower conversion.
- Gastrectomy, bariatric surgery, short bowel, chronic diarrhoea.
- Vomiting or GI intolerance forcing split or reduced dosing.
- Enzyme induction — rifampin lowers the exposure of many companion drugs, including moxifloxacin.
- Ordinary variability — isoniazid exposure varies several-fold by NAT2 acetylator status on an identical dose.
A serum level is a pharmacokinetic measurement, not an adherence test and not a diagnosis of failure. Interpretation against published target ranges, and any change in regimen or dose, is the treating physician's decision.
← TB therapeutic drug monitoring — service overview
Compliance note (AKS / Stark). Auspicious Laboratory does not pay for referrals and provides no items of value to ordering clinicians. Testing is performed on a physician order for a documented clinical purpose; results are reported to the ordering clinician. Test selection and medical necessity are the clinician's decision.
FAQ
- What does a low serum level actually prove?
- That on this occasion, at this time after an observed dose, the drug did not reach the concentration the regimen assumes. It points at absorption or dosing rather than at the organism - which is the difference between adjusting a dose and rebuilding a regimen.
- Which drugs should be measured in a slow responder?
- Most clinicians start with rifampin and isoniazid, the two that drive early bactericidal activity and where variability is greatest, and add pyrazinamide or the second-line agents the patient is on. All ten drugs on our menu are LC-MS/MS in serum.
- Does diabetes really change TB drug exposure?
- Diabetes is associated with lower rifampin exposure and slower culture conversion, on top of gastroparesis affecting absorption. It is one of the most common reasons a fully adherent patient is under-exposed.
References
- ATS / CDC / IDSA — Treatment of Drug-Resistant Tuberculosis.
- WHO — Consolidated guidelines on drug-resistant TB treatment (BPaL/BPaLM).
- CDC — TB clinical care.